COVID-19 Vaccination

alert icon

CDC and FDA have recommended a pause in the use of the Janssen (Johnson & Johnson) COVID-19 vaccine in the United States out of an abundance of caution, effective Tuesday, April 13. Of the 6.8 million Janssen COVID-19 vaccine doses administered in the United States to date, six cases of a type of blood clot called “cerebral venous sinus thrombosis” (CVST) were seen in combination with low levels of blood platelets (thrombocytopenia). CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14, to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.

If you are a COVID-19 Vaccination Provider with Janssen (Johnson & Johnson) vaccine:

  1. Mark any Janssen/J&J vaccine in your inventory “Do not use. Awaiting guidance.”
  2. Continue to store the vaccine in the refrigerator between 2°C and 8°C (36°F and 46°F).
  3. Follow vaccine storage practices and continue to monitor and document storage unit temperatures.

Clinical Resources for Each COVID-19 Vaccine

Find information for COVID-19 vaccination administration, storage and handing, reporting, and patient education for each specific vaccine

illustration of a group of healthcare providers in face masks

people icon
Vaccines for COVID-19: Information for You and Your Family

Individuals looking for information about COVID-19 vaccines should visit the COVID-19 website.

Routine Vaccination During a Pandemic

The COVID-19 pandemic is changing rapidly and requires different strategies to maintain clinical preventive services, including immunization. Find up-to-date guidance on routine vaccination and clinical practice.

email_03Get Email Updates

To receive email updates about this page, enter your email address:

Page last reviewed: February 26, 2021